Welcome to our dedicated page for Dyadic Intl Del SEC filings (Ticker: DYAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scanning Dyadic International’s filings for C1 platform breakthroughs or new licensing deals can feel like navigating a lab notebook written for regulators, not investors. That’s why Stock Titan organizes every Dyadic International insider trading Form 4 transactions record, 10-K narrative and 8-K material events explained in one place, then deploys AI-powered summaries to turn biotech jargon into clear takeaways.
Need the Dyadic International quarterly earnings report 10-Q filing to spot R&D burn rates or royalty revenue? Our engine delivers real-time alerts the moment the document hits EDGAR and produces concise highlights � revenue by segment, cash runway, pipeline milestones. Curious about governance? Review the Dyadic International proxy statement executive compensation tables or track Dyadic International executive stock transactions Form 4 without sifting through multiple PDFs. Each line item is linked to an expert note so you understand how share grants align with clinical progress.
Whether you’re comparing batches per fermenter or projecting vaccine scalability, understanding Dyadic International SEC documents with AI cuts research time drastically. Explore Dyadic International annual report 10-K simplified sections on manufacturing risk, dive into Dyadic International earnings report filing analysis for margin trends, or watch Dyadic International Form 4 insider transactions real-time before market moves. From initial idea to informed decision, our comprehensive coverage keeps every disclosure � including those hidden in exhibits � instantly accessible and crystal clear.
Dyadic International, Inc. (Nasdaq: DYAI) filed a Form 8-K on 2 July 2025 to disclose a branding update. In 30 days the company will begin operating under the business name “Dyadic Applied BioSolutions.� The filing clarifies that the legal corporate name remains “Dyadic International, Inc.,� the DYAI ticker is unchanged, and the company will continue to trade on the Nasdaq Stock Market. The disclosure is provided under Item 7.01 (Regulation FD) and is furnished—not filed—thereby carrying no Section 18 liability and no direct impact on financial statements. No financial data, operational revisions, or strategic transactions are included; the report solely communicates the forthcoming DBA designation and furnishes the related press release as Exhibit 99.1.
Dyadic International (NASDAQ:DYAI) filed an 8-K disclosing receipt of a Nasdaq Listing Rule 5550(b)(2) deficiency notice for failing to maintain the minimum $35 million Market Value of Listed Securities (MVLS).
The stock has been below the threshold for 30 consecutive business days, activating a 180-day cure period ending December 20, 2025. To regain compliance, DYAI’s MVLS must close at or above $35 million for at least 10 consecutive trading days before the deadline. Failure would prompt a delisting determination, which the company could appeal, though success is not assured.
The notice has no immediate effect on Nasdaq trading but flags heightened liquidity and financing risk. Management says it will monitor MVLS and “evaluate available options,� yet outlines no specific actions. Forward-looking statements reiterate ongoing losses, capital needs, and potential breaches of other listing standards, underscoring uncertainty for shareholders.
Dyadic International, Inc. (NASDAQ: DYAI) filed an 8-K to disclose the final results of its 20 June 2025 Annual Meeting of Shareholders.
- Director election � Class III: Founder & CEO Mark A. Emalfarb was re-elected to serve until the 2028 meeting with 15,946,385 votes FOR (96.0% of votes cast) versus 421,896 WITHHELD and 7,892,709 broker non-votes.
- Auditor ratification: Crowe LLP was confirmed as independent registered public accounting firm for FY-2025 with an overwhelming 24,013,307 FOR (99.0%), 237,523 AGAINST and 10,160 ABSTAIN.
- Say-on-pay (advisory): Compensation of named executive officers received 15,765,072 FOR (95.9%), 522,744 AGAINST, 80,465 ABSTAIN, and 7,892,709 broker non-votes.
- Say-on-pay frequency: Shareholders strongly preferred an annual advisory vote: 15,443,558 votes for 1-year, handily exceeding 716,692 (2-years) and 13,576 (3-years). Abstentions were 194,455.
Based on these results, the Board and its Compensation Committee have resolved that future advisory votes on executive compensation will be held once every year.
No other matters were brought before the meeting, and there were no disclosures of earnings, major transactions or material events beyond the voting outcomes.
Dyadic International, Inc. (DYAI) � Form 4 insider filing details the June 20, 2025 vesting and conversion of 10,776 restricted stock units (RSUs) held by outgoing director Michael P. Tarnok.
The RSUs automatically vested "upon retirement from service as a member of the board of directors," and were converted into an equal number of DYAI common shares. Transaction code M denotes an exempt, non-open-market conversion; no shares were sold and no cash price was paid (exercise price reported as $0).
Following the transaction Mr. Tarnok’s direct beneficial ownership rises to 281,033 common shares, reinforcing post-retirement equity alignment. The filing, signed June 24, 2025, indicates the action was performed by an attorney-in-fact on the insider’s behalf. No 10b5-1 trading plan box is checked, and there are no derivative instruments remaining.
For investors, the disclosure is largely administrative. The conversion results in a modest 0.04 % increase to Dyadic’s basic share count (based on ~26 M shares outstanding as of the last 10-K) and signals a board transition already in progress. No information on replacement directors, strategic impact, or cash compensation is provided in this filing.
Dyadic International, Inc. (DYAI) � Form 4 insider filing
Director Arindam Bose reported changes in his beneficial ownership effective 20 June 2025.
- Non-derivative transaction (Table I): Code M indicates the exercise/settlement of Restricted Stock Units (RSUs), resulting in the acquisition of 10,776 common shares. Post-transaction, Bose directly owns 61,535 DYAI shares.
- Derivative transactions (Table II): � One RSU grant (10,776 units) was settled into common stock (Code M). � A separate RSU grant of identical size was forfeited upon Bose’s retirement from the Board (Code D). No derivative securities remain outstanding for the reporting person.
- Reason for changes: Vested RSUs were converted to stock, while unvested RSUs were forfeited in connection with the director’s retirement.
The filing does not disclose any purchase price (exercise price shown as $0), suggesting these were cost-free equity settlements typical of service-based RSUs. The net effect is a shift of Bose’s exposure from derivative to direct equity ownership without cash inflow/outflow for DYAI. No additional corporate events, earnings data or large-scale insider sales are reported in this filing.
FAQ
What is the current stock price of Dyadic Intl Del (DYAI)?
What is the market cap of Dyadic Intl Del (DYAI)?
What is the core focus of Dyadic International Inc?
How does the C1 cell expression platform benefit protein manufacturing?
What role does the Dapibus� platform play in the company’s operations?
In which market segments does Dyadic International operate?
How does Dyadic generate revenue from its technologies?
What distinguishes Dyadic’s business model from its competitors?
What are some applications of Dyadic International’s technology platforms?
How does Dyadic ensure quality and regulatory compliance?
